NCTC
TEVA icon

New Covenant Trust Company’s Teva Pharmaceuticals TEVA Stock Holding History

New Covenant Trust Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,015
Closed -$28.4K – 369
2024
Q1 		$28.4K Buy
+2,015
New +$25.4K 0.03% 214

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

New Covenant Trust Company's TEVA Position: Q2 2024 in Review

New Covenant Trust Company sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 2,015 shares — an estimated $28.4K sold.

New Covenant Trust Company first reported a position in TEVA in Q1 2024 and held it in 1 quarter. The position peaked at $28.4K in Q1 2024. 533 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • New Covenant Trust Company reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • New Covenant Trust Company sold 2,015 Teva Pharmaceuticals shares in Q2 2024, an estimated $28.4K.
  • New Covenant Trust Company first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • New Covenant Trust Company's Teva Pharmaceuticals position peaked at $28.4K in Q1 2024.
  • 533 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on New Covenant Trust Company's 13F filing for Q2 2024, filed 30 Jul 2024.